VFA
CPRX

Virtus Fund Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Virtus Fund Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$28K Buy
1,340
+46
+4% +$988 0.09% 97
2024
Q3 		$25.7K Hold
1,294
– – 0.1% 98
2024
Q2 		$20K Buy
1,294
+266
+26% +$4.14K 0.08% 107
2024
Q1 		$16.4K Hold
1,028
– – 0.06% 111
2023
Q4 		$17.3K Hold
1,028
– – 0.11% 100
2023
Q3 		$12K Hold
1,028
– – 0.09% 98
2023
Q2 		$13.8K Hold
1,028
– – 0.1% 100
2023
Q1 		$17K Buy
+1,028
New +$17K 0.12% 102

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Virtus Fund Advisers's CPRX Position: Q4 2024 in Review

Virtus Fund Advisers increased its Catalyst Pharmaceutical (CPRX) stake by 3.6% in Q4 2024, buying an estimated $988 and bringing the position to 1,340 shares worth $28K. The position accounts for 0.09% of the portfolio, ranked #97.

Virtus Fund Advisers first reported a position in CPRX in Q1 2023 and has held it in 8 quarters since. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • Virtus Fund Advisers held 1,340 shares of Catalyst Pharmaceutical worth $28K as of Q4 2024.
  • Virtus Fund Advisers bought 46 Catalyst Pharmaceutical shares in Q4 2024, an estimated $988.
  • Catalyst Pharmaceutical made up 0.09% of Virtus Fund Advisers's portfolio in Q4 2024, its #97 holding.
  • Virtus Fund Advisers first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 8 quarters since.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Virtus Fund Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.